$ATOS
ATOSSA THERAPEUTICS, INC. Stock $atos

$atos Overview Financials Valuation SEC Filings Company Website

2013 Q2 Form 10-Q Financial Statement

#000114420413045866 Filed on August 14, 2013

Income Statement

Concept	2013 Q2	2012 Q4	2012 Q2
Revenue	$326.1K	$100.0K	$223.1K
YoY Change	46.16%
Cost Of Revenue	$222.2K	$10.00K	$17.79K
YoY Change	1148.93%	0.0%
Gross Profit	$103.9K	$90.00K	$205.3K
YoY Change	-49.38%
Gross Profit Margin	31.87%	90.0%	92.03%
Selling, General & Admin	$2.497M	$1.330M	$828.0K
YoY Change	201.59%	23.15%	13.43%
% of Gross Profit	2403.15%	1477.78%	403.31%
Research & Development	$190.0K	$470.0K	$543.1K
YoY Change	-65.02%
% of Gross Profit	182.79%	522.22%	264.52%
Depreciation & Amortization	$30.67K	$100.0K	$10.00K
YoY Change	206.68%	900.0%
% of Gross Profit	29.51%	111.11%	4.87%
Operating Expenses	$2.687M	$1.790M	$1.371M
YoY Change	95.99%	67.29%	87.82%
Operating Profit	-$2.583M	-$1.700M	-$1.166M
YoY Change	121.59%	58.88%	59.7%
Interest Expense	$352.00	$0.00	$2.446K
YoY Change	-85.61%	-100.0%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$2.584M	-$1.710M	-$1.168M
YoY Change	121.22%	44.92%	59.99%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$2.584M	-$1.710M	-$1.168M
YoY Change	121.22%	44.92%	59.99%
Net Earnings / Revenue	-792.36%	-1710.0%	-523.52%
Basic Earnings Per Share
Diluted Earnings Per Share	-$32.25M	-$19.00M	-$19.50M
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept	2013 Q2	2012 Q4	2012 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$2.400M	$1.700M	$100.0K
YoY Change	2300.0%	-10.53%
Cash & Equivalents	$2.440M	$1.725M	$88.00K
Short-Term Investments
Other Short-Term Assets	$2.300M	$100.0K	$500.0K
YoY Change	360.0%	-90.0%
Inventory		$0.00
Prepaid Expenses	$2.348M	$122.6K
Receivables	$520.4K	$141.7K	$200.0K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$5.355M	$1.989M	$700.0K
YoY Change	665.02%	-31.4%
LONG-TERM ASSETS
Property, Plant & Equipment	$205.8K	$160.0K	$100.0K
YoY Change	105.8%	59.97%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$4.494M	$4.677M	$0.00
YoY Change
Total Long-Term Assets	$4.700M	$4.837M	$100.0K
YoY Change	4599.87%	2318.32%
TOTAL ASSETS
Total Short-Term Assets	$5.355M	$1.989M	$700.0K
Total Long-Term Assets	$4.700M	$4.837M	$100.0K
Total Assets	$10.06M	$6.826M	$800.0K
YoY Change	1156.88%	120.2%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$184.0K	$68.22K	$100.0K
YoY Change	84.0%	-31.78%
Accrued Expenses	$1.559M	$1.582M	$1.100M
YoY Change	41.68%	295.6%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$300.0K
YoY Change	-100.0%	-100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$1.774M	$1.651M	$1.400M
YoY Change	26.73%	10.04%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.774M	$1.651M	$1.400M
Total Long-Term Liabilities	$0.00	$0.00	$0.00
Total Liabilities	$1.800M	$1.700M	$1.400M
YoY Change	28.57%	13.33%
SHAREHOLDERS EQUITY
Retained Earnings	-$14.26M	-$9.732M
YoY Change
Common Stock	$15.34K	$12.92K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$8.281M	$5.176M	-$600.0K
YoY Change
Total Liabilities & Shareholders Equity	$10.06M	$6.826M	$800.0K
YoY Change	1156.88%	120.2%

Cashflow Statement

Concept	2013 Q2	2012 Q4	2012 Q2
OPERATING ACTIVITIES
Net Income	-$2.584M	-$1.710M	-$1.168M
YoY Change	121.22%	44.92%	59.99%
Depreciation, Depletion And Amortization	$30.67K	$100.0K	$10.00K
YoY Change	206.68%	900.0%
Cash From Operating Activities	-$2.110M	-$1.930M	-$810.0K
YoY Change	160.49%	85.58%	-26.36%
INVESTING ACTIVITIES
Capital Expenditures	-$80.00K	-$130.0K	$0.00
YoY Change		160.0%	-100.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$80.00K	-$130.0K	$0.00
YoY Change		160.0%	-100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	3.250M	3.370M	0.000
YoY Change			-100.0%
NET CHANGE
Cash From Operating Activities	-2.110M	-1.930M	-810.0K
Cash From Investing Activities	-80.00K	-130.0K	0.000
Cash From Financing Activities	3.250M	3.370M	0.000
Net Change In Cash	1.060M	1.310M	-810.0K
YoY Change	-230.86%	-220.18%	-118.58%
FREE CASH FLOW
Cash From Operating Activities	-$2.110M	-$1.930M	-$810.0K
Capital Expenditures	-$80.00K	-$130.0K	$0.00
Free Cash Flow	-$2.030M	-$1.800M	-$810.0K
YoY Change	150.62%	81.82%	-21.36%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2012Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2013Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2012Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2013Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2013Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2012Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2013Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2012Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2013Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2012Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2013Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	75000000	shares
CY2012Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	75000000	shares
CY2013Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	15338074	shares
CY2012Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	12919367	shares
CY2013Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	15338074	shares
CY2012Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	12919367	shares
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1725197	USD
CY2013Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	520424	USD
CY2012Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	141665	USD
CY2013Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	2347701	USD
CY2012Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	122633	USD
CY2013Q2	us-gaap	Assets Current AssetsCurrent	5355137	USD
CY2012Q4	us-gaap	Assets Current AssetsCurrent	1989495	USD
CY2013Q2	atos	Furniture And Equipment Net FurnitureAndEquipmentNet	205800	USD
CY2012Q4	atos	Furniture And Equipment Net FurnitureAndEquipmentNet	159967	USD
CY2013Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	205800	USD
CY2012Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	159967	USD
	us-gaap	Sales Revenue Net SalesRevenueNet	992090	USD
CY2013Q2	us-gaap	Liabilities Current LiabilitiesCurrent	1774170	USD
CY2012Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1650598	USD
CY2013Q2	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2012Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2013Q2	us-gaap	Common Stock Value CommonStockValue	15338	USD
CY2012Q4	us-gaap	Common Stock Value CommonStockValue	12919	USD
CY2013Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	22522539	USD
CY2012Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	14894522	USD
CY2013Q2	us-gaap	Security Deposit SecurityDeposit	36446	USD
CY2012Q4	us-gaap	Security Deposit SecurityDeposit	36447	USD
CY2013Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	4457619	USD
CY2012Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	4640224	USD
CY2013Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	4494065	USD
CY2012Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	4676671	USD
CY2013Q2	us-gaap	Assets Assets	10055002	USD
CY2012Q4	us-gaap	Assets Assets	6826133	USD
CY2013Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	184002	USD
CY2012Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	68217	USD
CY2013Q2	atos	Accrued Expenses Current AccruedExpensesCurrent	1289104	USD
CY2012Q4	atos	Accrued Expenses Current AccruedExpensesCurrent	1374385	USD
CY2013Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-14257045	USD
CY2012Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-9731906	USD
CY2013Q2	us-gaap	Stockholders Equity StockholdersEquity	8280832	USD
CY2012Q4	us-gaap	Stockholders Equity StockholdersEquity	5175535	USD
CY2013Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	10055002	USD
CY2012Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	6826133	USD
CY2013Q2	us-gaap	Deposits Assets Current DepositsAssetsCurrent	47500	USD
CY2012Q4	us-gaap	Deposits Assets Current DepositsAssetsCurrent	0	USD
CY2013Q2	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	72537	USD
CY2012Q4	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	0	USD
CY2013Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	196873	USD
CY2012Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	207996	USD
CY2013Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	31654	USD
CY2013Q2	atos	Diagnostic Testing Service DiagnosticTestingService	120488	USD
CY2012Q2	atos	Diagnostic Testing Service DiagnosticTestingService	219972	USD
	atos	Diagnostic Testing Service DiagnosticTestingService	765120	USD
CY2013Q2	atos	Product Sales ProductSales	205590	USD
CY2012Q2	atos	Product Sales ProductSales	3125	USD
	atos	Product Sales ProductSales	226970	USD
CY2013Q2	us-gaap	Sales Revenue Net SalesRevenueNet	326078	USD
CY2012Q2	us-gaap	Sales Revenue Net SalesRevenueNet	223097	USD
CY2013Q2	us-gaap	Cost Of Services CostOfServices	2356	USD
CY2012Q2	us-gaap	Cost Of Services CostOfServices	17788	USD
	us-gaap	Cost Of Services CostOfServices	85700	USD
CY2013Q2	us-gaap	Cost Of Goods Sold CostOfGoodsSold	219804	USD
CY2012Q2	us-gaap	Cost Of Goods Sold CostOfGoodsSold	0	USD
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	243833	USD
CY2013Q2	us-gaap	Cost Of Revenue CostOfRevenue	222160	USD
CY2012Q2	us-gaap	Cost Of Revenue CostOfRevenue	17788	USD
	us-gaap	Cost Of Revenue CostOfRevenue	329533	USD
CY2012Q2	atos	Loss On Reduction Of Inventory To Lower Of Cost Or Market LossOnReductionOfInventoryToLowerOfCostOrMarket	0	USD
	atos	Loss On Reduction Of Inventory To Lower Of Cost Or Market LossOnReductionOfInventoryToLowerOfCostOrMarket	121910	USD
CY2013Q2	us-gaap	Selling Expense SellingExpense	319390	USD
	us-gaap	Cost Of Revenue CostOfRevenue	288624	USD
	us-gaap	Cost Of Revenue CostOfRevenue	20985	USD
CY2012Q2	us-gaap	Selling Expense SellingExpense	123832	USD
CY2013Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	189955	USD
CY2012Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	543081	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3967533	USD
CY2013Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2177920	USD
CY2012Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	704208	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	9565126	USD
CY2013Q2	us-gaap	Operating Expenses OperatingExpenses	2687265	USD
CY2012Q2	us-gaap	Operating Expenses OperatingExpenses	1371121	USD
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	8722843	shares
	us-gaap	Profit Loss ProfitLoss	-4525139	USD
	us-gaap	Operating Expenses OperatingExpenses	14764500	USD
CY2013Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-2583347	USD
CY2012Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-1165812	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-14223853	USD
CY2013Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	0	USD
CY2012Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	310	USD
	atos	Product Sales ProductSales	5125	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	6588	USD
CY2013Q2	us-gaap	Interest Expense InterestExpense	352	USD
CY2012Q2	us-gaap	Interest Expense InterestExpense	2446	USD
	us-gaap	Interest Expense InterestExpense	39530	USD
CY2013Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-2583699	USD
CY2012Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-1167948	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-14256795	USD
CY2013Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	250	USD
CY2013Q2	us-gaap	Net Income Loss NetIncomeLoss	-2583699	USD
CY2012Q2	us-gaap	Net Income Loss NetIncomeLoss	-1167948	USD
	us-gaap	Net Income Loss NetIncomeLoss	-14257045	USD
CY2013Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.17
CY2012Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.10
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.63
	atos	Diagnostic Testing Service DiagnosticTestingService	289718	USD
	atos	Diagnostic Testing Service DiagnosticTestingService	272685	USD
	atos	Product Sales ProductSales	219030	USD
	us-gaap	Sales Revenue Net SalesRevenueNet	508748	USD
	us-gaap	Sales Revenue Net SalesRevenueNet	277810	USD
	us-gaap	Cost Of Services CostOfServices	49955	USD
	us-gaap	Cost Of Services CostOfServices	20985	USD
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	238669	USD
	us-gaap	Gross Profit GrossProfit	220124	USD
	us-gaap	Gross Profit GrossProfit	233018	USD
	us-gaap	Selling Expense SellingExpense	591965	USD
	us-gaap	Selling Expense SellingExpense	194267	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	410147	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	961071	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3742792	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1305660	USD
	us-gaap	Operating Expenses OperatingExpenses	4744904	USD
	us-gaap	Operating Expenses OperatingExpenses	2460998	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-4524780	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-2227980	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	0	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	1173	USD
	us-gaap	Interest Expense InterestExpense	4060	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-4525139	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-2230867	USD
	us-gaap	Net Income Loss NetIncomeLoss	-4525139	USD
	us-gaap	Net Income Loss NetIncomeLoss	-2230867	USD
	atos	Loss On Reduction Of Inventory To Lower Of Cost Or Market LossOnReductionOfInventoryToLowerOfCostOrMarket	0	USD
	atos	Loss On Reduction Of Inventory To Lower Of Cost Or Market LossOnReductionOfInventoryToLowerOfCostOrMarket	23807	USD
	us-gaap	Interest Expense InterestExpense	359	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	0	USD
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.32
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.20
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	14120962	shares
CY2012Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2013Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	14808728	shares
CY2012Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	11256867	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	11256867	shares
	atos	Common Shares Issued For Services CommonSharesIssuedForServices	0	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	1011820	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	70662	USD
	us-gaap	Profit Loss ProfitLoss	-2230867	USD
	atos	Common Shares Issued For Services CommonSharesIssuedForServices	181798	USD
	atos	Loan Initiation Fee Accrued For Notes Payable LoanInitiationFeeAccruedForNotesPayable	0	USD
	atos	Loan Initiation Fee Accrued For Notes Payable LoanInitiationFeeAccruedForNotesPayable	0	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	226643	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	17057	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	378759	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	177055	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	20323	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	23807	USD
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	36526	USD
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	149956	USD
	us-gaap	Increase Decrease In Security Deposits IncreaseDecreaseInSecurityDeposits	-47500	USD
	us-gaap	Increase Decrease In Security Deposits IncreaseDecreaseInSecurityDeposits	-32789	USD
	us-gaap	Payments To Acquire Furniture And Fixtures PaymentsToAcquireFurnitureAndFixtures	81370	USD
	us-gaap	Payments To Acquire Furniture And Fixtures PaymentsToAcquireFurnitureAndFixtures	0	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-89870	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0	USD
	atos	Proceeds From Issuance Of Common Stock And Warrants ProceedsFromIssuanceOfCommonStockAndWarrants	4248275	USD
	atos	Proceeds From Issuance Of Common Stock And Warrants ProceedsFromIssuanceOfCommonStockAndWarrants	0	USD
	us-gaap	Proceeds From Repayments Of Lines Of Credit ProceedsFromRepaymentsOfLinesOfCredit	0	USD
	us-gaap	Proceeds From Repayments Of Lines Of Credit ProceedsFromRepaymentsOfLinesOfCredit	-750000	USD
	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt	0	USD
	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt	-6178	USD
	atos	Proceeds From Repayments Of Commercial Line Of Credit ProceedsFromRepaymentsOfCommercialLineOfCredit	0	USD
	atos	Proceeds From Repayments Of Commercial Line Of Credit ProceedsFromRepaymentsOfCommercialLineOfCredit	750000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	4248275	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-6178	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	714315	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-1822824	USD
CY2011Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1910821	USD
CY2013Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2439512	USD
CY2012Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	87997	USD
	us-gaap	Interest Paid InterestPaid	359	USD
	us-gaap	Interest Paid InterestPaid	6036	USD
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	USD
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	USD
	atos	Common Stock And Warrants Issued For Assets Purchase CommonStockAndWarrantsIssuedForAssetsPurchase	0	USD
	atos	Common Stock And Warrants Issued For Assets Purchase CommonStockAndWarrantsIssuedForAssetsPurchase	0	USD
	atos	Options Issued For Previously Accrued Director Compensation OptionsIssuedForPreviouslyAccruedDirectorCompensation	0	USD
	atos	Options Issued For Previously Accrued Director Compensation OptionsIssuedForPreviouslyAccruedDirectorCompensation	0	USD
	us-gaap	Profit Loss ProfitLoss	-14257045	USD
	atos	Common Shares Issued For Services CommonSharesIssuedForServices	252798	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	1304084	USD
	atos	Loan Initiation Fee Accrued For Notes Payable LoanInitiationFeeAccruedForNotesPayable	2000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	372818	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	520424	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	142233	USD
	us-gaap	Increase Decrease In Security Deposits IncreaseDecreaseInSecurityDeposits	-83948	USD
	us-gaap	Payments To Acquire Furniture And Fixtures PaymentsToAcquireFurnitureAndFixtures	272417	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-361383	USD
	atos	Proceeds From Issuance Of Common Stock And Warrants ProceedsFromIssuanceOfCommonStockAndWarrants	14072601	USD
	us-gaap	Proceeds From Repayments Of Lines Of Credit ProceedsFromRepaymentsOfLinesOfCredit	0	USD
	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt	-2000	USD
	atos	Proceeds From Repayments Of Commercial Line Of Credit ProceedsFromRepaymentsOfCommercialLineOfCredit	0	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	14070601	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	2439513	USD
CY2009Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	0	USD
	us-gaap	Interest Paid InterestPaid	33066	USD
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	250	USD
	atos	Common Stock And Warrants Issued For Assets Purchase CommonStockAndWarrantsIssuedForAssetsPurchase	4674853	USD
	atos	Options Issued For Previously Accrued Director Compensation OptionsIssuedForPreviouslyAccruedDirectorCompensation	45000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	115785	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	6702	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	184002	USD
	atos	Increase Decrease In Deferred Rent IncreaseDecreaseInDeferredRent	72537	USD
	atos	Increase Decrease In Deferred Rent IncreaseDecreaseInDeferredRent	0	USD
	atos	Increase Decrease In Deferred Rent IncreaseDecreaseInDeferredRent	72537	USD
	atos	Loss On Reduction Of Inventory LossOnReductionOfInventory	20323	USD
	atos	Loss On Reduction Of Inventory LossOnReductionOfInventory	23807	USD
	atos	Loss On Reduction Of Inventory LossOnReductionOfInventory	142233	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-85280	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	679600	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	1542101	USD
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	31654	USD
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	0	USD
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	31654	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3444090	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-11269705	USD
	us-gaap	Payments To Acquire Software PaymentsToAcquireSoftware	8500	USD
	us-gaap	Payments To Acquire Software PaymentsToAcquireSoftware	0	USD
	us-gaap	Payments To Acquire Software PaymentsToAcquireSoftware	88966	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1816646	USD
	atos	Increase Decrease In Accrued Payroll IncreaseDecreaseInAccruedPayroll	0	USD
	atos	Increase Decrease In Accrued Payroll IncreaseDecreaseInAccruedPayroll	-11123	USD
	atos	Increase Decrease In Accrued Payroll IncreaseDecreaseInAccruedPayroll	-11123	USD
	atos	Commitment Shares Issued For Shares Distributed For Capital Contribution CommitmentSharesIssuedForSharesDistributedForCapitalContribution	2387250	USD
	atos	Commitment Shares Issued For Shares Distributed For Capital Contribution CommitmentSharesIssuedForSharesDistributedForCapitalContribution	0	USD
	atos	Commitment Shares Issued For Shares Distributed For Capital Contribution CommitmentSharesIssuedForSharesDistributedForCapitalContribution	2387250	USD
	atos	Amortization Of Commitment Shares Issued For Shares Distributed For Capital Contribution AmortizationOfCommitmentSharesIssuedForSharesDistributedForCapitalContribution	198958	USD
	atos	Amortization Of Commitment Shares Issued For Shares Distributed For Capital Contribution AmortizationOfCommitmentSharesIssuedForSharesDistributedForCapitalContribution	0	USD
	atos	Amortization Of Commitment Shares Issued For Shares Distributed For Capital Contribution AmortizationOfCommitmentSharesIssuedForSharesDistributedForCapitalContribution	198958	USD
	us-gaap	Nature Of Operations NatureOfOperations	<div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <strong>NOTE 1: NATURE OF OPERATIONS</strong></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <strong> </strong></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> The Company’s operations began in December 2008 with the negotiations for the acquisition of the Mammary Aspirate Specimen Cytology Test System, or the MASCT System, patent rights and assignments and the FDA <font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">clearances</font> for marketing, which acquisition was completed in January 2009. Atossa Genetics Inc. (the “Company”) was incorporated on April 30, 2009 in the State of Delaware. The Company was formed to develop and market the MASCT System, a cellular and molecular diagnostic risk assessment product for the detection of pre-cancerous changes that could lead to breast cancer. The Company’s fiscal year ends on December 31st.</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> In December 2011 the Company established the National Reference Laboratory for Breast Health, or NRLBH, as a wholly-owned subsidiary. NRLBH is the Company’s CLIA-certified laboratory where the ForeCYTE and ArgusCYTE test specimens are examined for the presence of normal, pre-malignant, or malignant changes as determined by cytopathology and biomarkers . These test results provide patients and physicians with information about the care path that should be followed, depending on the individual risk of future cancer as determined by the results.</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> In September 2012, the Company acquired the assets of Acueity Healthcare, Inc. (“Acueity”). The purchased assets included 35 issued patents (18 issued in the U.S. and 17 issued in foreign countries) and 41 patent applications (32 in the U.S. and 9 in foreign countries), six 510(k) FDA marketing authorizations related to the manufacturing, use, and sale of the Viaduct Miniscope and accessories, the Manoa Breast Biopsy system, the Excisor Bioptome, the Acueity Medical Light Source, the Viaduct Microendoscope and accessories, and cash in the amount of $<font style=" FONT-SIZE: 10pt">400,000</font>. The microendoscopes are less than 0.9 mm outside diameter and can be inserted into a milk duct. This permits a physician to pass a microendoscope into the milk duct system of the breast and view the duct system via fiberoptic video images. Abnormalities that are visualized can then be biopsied from inside the duct with the biopsy tools that are inserted adjacent to the microendoscope. The patents relate to intraductal diagnostic and therapeutic devices and methods of use. The Company did not, however, acquire an inventory of these diagnostic tools, manufacturing capabilities or any personnel to market and sell the tools. The Company cannot provide any assurance that it will be successful commercializing these tools.</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <u>Development Stage Risk</u></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> From April 30, 2009 (inception) through June 30, 2013, the Company earned $<font style=" FONT-SIZE: 10pt">992,090</font> in revenue from the sale of its products and laboratory services. The Company’s activities have been accounted for as those of a “Development Stage Enterprise” as set forth in Accounting Standards Codification (“ASC”) 915 “Development Stage Entities”, which was previously Statement of Financial Accounting Standards No. 7 (“SFAS 7”). Among the disclosures required by ASC 915 are that the Company’s financial statements be identified as those of a development stage company, and that the statements of operations, stockholders’ equity and cash flows disclose activity since the date of the Company’s inception.</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> Since its inception, the Company has been dependent upon the receipt of capital investment to fund its continuing activities. In addition to the normal risks associated with a new business venture, there can be no assurance that the Company’s business plan will be successfully executed. The Company’s ability to execute its business plan will depend on its ability to obtain additional financing and achieve a profitable level of operations. There can be no assurance that sufficient financing will be obtained. Further, the Company cannot give any assurance that it will generate substantial revenue or that its business operations will prove to be profitable.</div> </div>
	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	400000	USD
	us-gaap	Use Of Estimates UseOfEstimates	<div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <strong>Use of Estimates:</strong></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> The preparation of consolidated financial statements in conformity with generally accepted accounting principles in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Accordingly, actual results could differ from those estimates.</div> </div>
CY2012	atos	Loss On Reduction Of Inventory LossOnReductionOfInventory	29884	USD
CY2013Q2	atos	Prepaid Stock Purchase Agreement Service Fee PrepaidStockPurchaseAgreementServiceFee	2188542	USD
CY2012Q4	atos	Prepaid Stock Purchase Agreement Service Fee PrepaidStockPurchaseAgreementServiceFee	0	USD
CY2013Q2	us-gaap	Prepaid Insurance PrepaidInsurance	52864	USD
CY2012Q4	us-gaap	Prepaid Insurance PrepaidInsurance	62551	USD
CY2013Q2	atos	Prepaid Maintenance And Support Service Fee PrepaidMaintenanceAndSupportServiceFee	37867	USD
CY2012Q4	atos	Prepaid Maintenance And Support Service Fee PrepaidMaintenanceAndSupportServiceFee	20000	USD
CY2013Q2	us-gaap	Prepaid Taxes PrepaidTaxes	35950	USD
CY2012Q4	us-gaap	Prepaid Taxes PrepaidTaxes	40082	USD
CY2013Q2	us-gaap	Prepaid Rent PrepaidRent	25629	USD
CY2013Q2	us-gaap	Prepaid Advertising PrepaidAdvertising	6849	USD
CY2012Q4	us-gaap	Prepaid Advertising PrepaidAdvertising	0	USD
	us-gaap	Depreciation Depreciation	35537	USD
	us-gaap	Depreciation Depreciation	8647	USD
CY2013Q2	us-gaap	Finite Lived Patents Gross FiniteLivedPatentsGross	4704853	USD
CY2012Q4	us-gaap	Finite Lived Patents Gross FiniteLivedPatentsGross	4704853	USD
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.79
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.48
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y4M10D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y7M2D
CY2013Q2	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	178752	USD
CY2012Q4	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	97383	USD
CY2013Q2	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	93665	USD
CY2012Q4	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	93665	USD
CY2013Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	66617	USD
CY2012Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	31081	USD
CY2013Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	382683	USD
CY2013Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	366022	USD
CY2013Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	364681	USD
CY2013Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	363028	USD
CY2013Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	363028	USD
CY2013Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	2618177	USD
CY2013Q2	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	58966	USD
CY2012Q4	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	50466	USD
CY2013Q2	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	169375	USD
CY2012Q4	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	189131	USD
CY2013Q2	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	27498	USD
CY2012Q4	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	18866	USD
CY2013Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1558514	USD
CY2012Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1582382	USD
CY2013Q2	atos	Total Shares Authorized TotalSharesAuthorized	85000000	shares
CY2010Q3	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	1-for-2.26332
CY2012Q4	atos	Total Shares Authorized TotalSharesAuthorized	85000000	shares
CY2013Q2	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	USD
CY2013Q2	us-gaap	Cash Uninsured Amount CashUninsuredAmount	2189512	USD
CY2012Q4	us-gaap	Cash Uninsured Amount CashUninsuredAmount	1475197	USD
CY2013Q2	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	0	USD
CY2013Q2	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	456706	USD
CY2013Q2	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	323969	USD
CY2013Q2	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	132737	USD
CY2013Q2	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	0	USD
CY2013Q2	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	0	USD
CY2013Q2	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	0	USD
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	3727412	USD
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	1150416	USD
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	520835	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	1302654	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	12709	shares
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	1466035	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	339199	shares
CY2012Q4	atos	Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	824549000	USD
	atos	Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2592353000	USD
	atos	Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	719032000	USD
	atos	Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue	15623000	USD
CY2013Q2	atos	Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	2678877000	USD
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1052137	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1302654	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	0	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	12709	shares
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	5546	shares
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2336536	shares
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	870501	shares
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	2178857	shares
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.78
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	5.02
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	0
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	3.10
	atos	Warrant Terms WarrantTerms	P5Y
CY2012Q3	us-gaap	Share Price SharePrice	5.00
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P8Y3M4D
	atos	Share Based Compensation Arrangement By Share Based Payment Award Options Grant Date ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDate	2011-09-01
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	4.35
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	4.48
	atos	Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Exercised Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisedWeightedAverageGrantDateFairValue	3370000	USD
	us-gaap	Stock Issued During Period Shares Acquisitions StockIssuedDuringPeriodSharesAcquisitions	862500	shares
	atos	Warrants Issued During Period Acquisitions WarrantsIssuedDuringPeriodAcquisitions	325000	shares
	atos	Warrants Exercise Price WarrantsExercisePrice	5.00
	atos	Warrant Price WarrantPrice	2.3457

Files In Submission

Name	View Source	Status
0001144204-13-045866-index-headers.html	Edgar Link	pending
0001144204-13-045866-index.html	Edgar Link	pending
0001144204-13-045866.txt	Edgar Link	pending
0001144204-13-045866-xbrl.zip	Edgar Link	pending
atos-20130630.xml	Edgar Link	completed
atos-20130630.xsd	Edgar Link	pending
atos-20130630_cal.xml	Edgar Link	unprocessable
atos-20130630_def.xml	Edgar Link	unprocessable
atos-20130630_lab.xml	Edgar Link	unprocessable
atos-20130630_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
R1.htm	Edgar Link	pending
R1.xml	Edgar Link	unprocessable
R10.htm	Edgar Link	pending
R10.xml	Edgar Link	unprocessable
R11.htm	Edgar Link	pending
R11.xml	Edgar Link	unprocessable
R12.htm	Edgar Link	pending
R12.xml	Edgar Link	unprocessable
R13.htm	Edgar Link	pending
R13.xml	Edgar Link	unprocessable
R14.htm	Edgar Link	pending
R14.xml	Edgar Link	unprocessable
R15.htm	Edgar Link	pending
R15.xml	Edgar Link	unprocessable
R16.htm	Edgar Link	pending
R16.xml	Edgar Link	unprocessable
R17.htm	Edgar Link	pending
R17.xml	Edgar Link	unprocessable
R18.htm	Edgar Link	pending
R18.xml	Edgar Link	unprocessable
R19.htm	Edgar Link	pending
R19.xml	Edgar Link	unprocessable
R2.htm	Edgar Link	pending
R2.xml	Edgar Link	unprocessable
R20.htm	Edgar Link	pending
R20.xml	Edgar Link	unprocessable
R21.htm	Edgar Link	pending
R21.xml	Edgar Link	unprocessable
R22.htm	Edgar Link	pending
R22.xml	Edgar Link	unprocessable
R23.htm	Edgar Link	pending
R23.xml	Edgar Link	unprocessable
R24.htm	Edgar Link	pending
R24.xml	Edgar Link	unprocessable
R25.htm	Edgar Link	pending
R25.xml	Edgar Link	unprocessable
R26.htm	Edgar Link	pending
R26.xml	Edgar Link	unprocessable
R27.htm	Edgar Link	pending
R27.xml	Edgar Link	unprocessable
R28.htm	Edgar Link	pending
R28.xml	Edgar Link	unprocessable
R29.htm	Edgar Link	pending
R29.xml	Edgar Link	unprocessable
R3.htm	Edgar Link	pending
R3.xml	Edgar Link	unprocessable
R30.htm	Edgar Link	pending
R30.xml	Edgar Link	unprocessable
R31.htm	Edgar Link	pending
R31.xml	Edgar Link	unprocessable
R32.htm	Edgar Link	pending
R32.xml	Edgar Link	unprocessable
R33.htm	Edgar Link	pending
R33.xml	Edgar Link	unprocessable
R34.htm	Edgar Link	pending
R34.xml	Edgar Link	unprocessable
R35.htm	Edgar Link	pending
R35.xml	Edgar Link	unprocessable
R36.htm	Edgar Link	pending
R36.xml	Edgar Link	unprocessable
R37.htm	Edgar Link	pending
R37.xml	Edgar Link	unprocessable
R38.htm	Edgar Link	pending
R38.xml	Edgar Link	unprocessable
R39.htm	Edgar Link	pending
R39.xml	Edgar Link	unprocessable
R4.htm	Edgar Link	pending
R4.xml	Edgar Link	unprocessable
R40.htm	Edgar Link	pending
R40.xml	Edgar Link	unprocessable
R41.htm	Edgar Link	pending
R41.xml	Edgar Link	unprocessable
R42.htm	Edgar Link	pending
R42.xml	Edgar Link	unprocessable
R43.htm	Edgar Link	pending
R43.xml	Edgar Link	unprocessable
R44.htm	Edgar Link	pending
R44.xml	Edgar Link	unprocessable
R45.htm	Edgar Link	pending
R45.xml	Edgar Link	unprocessable
R46.htm	Edgar Link	pending
R46.xml	Edgar Link	unprocessable
R47.htm	Edgar Link	pending
R47.xml	Edgar Link	unprocessable
R48.htm	Edgar Link	pending
R48.xml	Edgar Link	unprocessable
R49.htm	Edgar Link	pending
R49.xml	Edgar Link	unprocessable
R5.htm	Edgar Link	pending
R5.xml	Edgar Link	unprocessable
R50.htm	Edgar Link	pending
R50.xml	Edgar Link	unprocessable
R51.htm	Edgar Link	pending
R51.xml	Edgar Link	unprocessable
R6.htm	Edgar Link	pending
R6.xml	Edgar Link	unprocessable
R7.htm	Edgar Link	pending
R7.xml	Edgar Link	unprocessable
R8.htm	Edgar Link	pending
R8.xml	Edgar Link	unprocessable
R9.htm	Edgar Link	pending
R9.xml	Edgar Link	unprocessable
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
v350682_10q.htm	Edgar Link	pending
v350682_ex31-1.htm	Edgar Link	pending
v350682_ex31-2.htm	Edgar Link	pending
v350682_ex32-1.htm	Edgar Link	pending
v350682_ex32-2.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ATOS
ATOSSA THERAPEUTICS, INC. Stock $atos

2013 Q2 Form 10-Q Financial Statement

#000114420413045866 Filed on August 14, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ATOS ATOSSA THERAPEUTICS, INC. Stock $atos

2013 Q2 Form 10-Q Financial Statement

#000114420413045866 Filed on August 14, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ATOS
ATOSSA THERAPEUTICS, INC. Stock $atos